# JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

> **NCT04418167** · PHASE1 · SUSPENDED · sponsor: **JS InnoPharm, LLC** · enrollment: 71 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** JSI-1187
- **DRUG:** Dabrafenib

## Key facts

- **NCT ID:** NCT04418167
- **Lead sponsor:** JS InnoPharm, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2020-06-18
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418167, "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04418167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*